Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-04-16

Clinical Trial Update: Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating adjuvant gefitinib (Iressa) for resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gefitinib (Gefitinib)

Snippet

Sponsor: Tan Tock Seng Hospital | Conditions: Liver Cancer | Phase 2 | Status: UNKNOWN